loading
전일 마감가:
$16.07
열려 있는:
$16.18
하루 거래량:
1.74M
Relative Volume:
0.96
시가총액:
$2.26B
수익:
$181.74M
순이익/손실:
$-143.97M
주가수익비율:
-11.80
EPS:
-1.39
순현금흐름:
$9.60M
1주 성능:
+8.39%
1개월 성능:
+13.73%
6개월 성능:
-37.74%
1년 성능:
-28.54%
1일 변동 폭
Value
$16.08
$16.88
1주일 범위
Value
$15.22
$17.19
52주 변동 폭
Value
$9.57
$30.41

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name
명칭
Arrowhead Pharmaceuticals Inc
Name
전화
626-696-4702
Name
주소
177 E COLORADO BLVD, PASADENA, CA
Name
직원
609
Name
트위터
@ArrowheadPharma
Name
다음 수익 날짜
2025-02-10
Name
최신 SEC 제출 서류
Name
ARWR's Discussions on Twitter

ARWR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ARWR
Arrowhead Pharmaceuticals Inc
16.40 2.12B 181.74M -143.97M 9.60M -1.39
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-06-05 개시 Goldman Neutral
2023-12-04 개시 BofA Securities Buy
2023-09-19 개시 Citigroup Neutral
2023-07-21 개시 TD Cowen Outperform
2023-05-12 다운그레이드 SVB Securities Outperform → Market Perform
2023-04-26 개시 SMBC Nikko Outperform
2023-04-12 업그레이드 SVB Securities Market Perform → Outperform
2023-03-21 개시 Bernstein Mkt Perform
2022-09-09 개시 Morgan Stanley Equal-Weight
2022-05-11 업그레이드 Robert W. Baird Neutral → Outperform
2022-01-19 재개 Goldman Buy
2021-08-06 재확인 Chardan Capital Markets Buy
2021-06-04 재개 Robert W. Baird Neutral
2021-02-05 재확인 H.C. Wainwright Buy
2020-12-21 다운그레이드 Robert W. Baird Outperform → Neutral
2020-12-16 개시 UBS Buy
2020-11-19 개시 Citigroup Buy
2020-05-13 개시 RBC Capital Mkts Outperform
2020-05-08 업그레이드 Oppenheimer Perform → Outperform
2020-04-15 업그레이드 Cantor Fitzgerald Neutral → Overweight
2020-03-24 업그레이드 SVB Leerink Underperform → Mkt Perform
2020-03-17 개시 Goldman Neutral
2020-01-21 개시 SVB Leerink Underperform
2019-12-13 개시 Oppenheimer Perform
2019-11-29 재확인 Chardan Capital Markets Buy
2019-11-27 재확인 B. Riley FBR Buy
2019-11-25 업그레이드 Robert W. Baird Neutral → Outperform
2019-10-24 다운그레이드 Robert W. Baird Outperform → Neutral
2019-10-22 재확인 Chardan Capital Markets Buy
2019-10-03 개시 Robert W. Baird Outperform
2018-09-07 업그레이드 B. Riley FBR Neutral → Buy
2018-09-06 재확인 Chardan Capital Markets Buy
2018-08-08 재확인 Cantor Fitzgerald Overweight
2018-07-02 재확인 Chardan Capital Markets Buy
모두보기

Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스

pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 31, 2025
pulisher
May 30, 2025

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - BioSpace

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences | ARWR Stock News - GuruFocus

May 29, 2025
pulisher
May 24, 2025

Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com

May 24, 2025
pulisher
May 20, 2025

Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 19, 2025
pulisher
May 18, 2025

Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 18, 2025

B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World

May 18, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 17, 2025
pulisher
May 17, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - Defense World

May 17, 2025
pulisher
May 16, 2025

ARWR: Multiple Value Drivers for Long-Term Growth - Research Tree

May 16, 2025
pulisher
May 16, 2025

Q3 Earnings Forecast for ARWR Issued By Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 16, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 16, 2025
pulisher
May 15, 2025

Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks

May 15, 2025
pulisher
May 15, 2025

Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum - MSN

May 15, 2025
pulisher
May 15, 2025

ARWR July 18th Options Begin Trading - Nasdaq

May 15, 2025
pulisher
May 15, 2025

ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Citigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00 - Defense World

May 15, 2025
pulisher
May 14, 2025

UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat - Defense World

May 14, 2025
pulisher
May 14, 2025

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus

May 14, 2025
pulisher
May 13, 2025

RBC cuts Arrowhead Pharma target to $40; keeps Outperform By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highl - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - BioSpace

May 12, 2025
pulisher
May 12, 2025

Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2 - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals Swings to Fiscal Q2 Earnings; Shares Rise After Hours - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals soars 7% on massive earnings beat By Investing.com - Investing.com South Africa

May 12, 2025

Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
자본화:     |  볼륨(24시간):